We are building and advancing a portfolio through global approval by establishing strong ties and collaborations with endocrinologists, the medical community at large and patient advocacy organizations worldwide.
Our goal is to provide physicians with new therapeutic strategies to improve the lives of their patients with rare endocrine and related diseases. Currently, our development pipeline includes two therapeutic peptide programs: AZP-3601 for the treatment of hypoparathyroidism and AZP-3813 for the treatment of acromegaly. Simultaneously, we continue to build our pipeline and have an on-going research program for a novel therapeutic peptide candidate, AZP-3404. We also continuously look for external innovation in rare endocrine and related diseases.
Our global management team is composed of a highly dedicated group of senior executives with proven drug development, registration and commercialization, and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and related disease.
We are supported by an impressive board of directors and strong international syndicate of investors, as well as a robust IP portfolio and key academic collaborations.
Our global management team is composed of a highly dedicated group of senior executives with proven drug development expertise and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and metabolic disorders.
Thierry Abribat, Ph.D.
Founder and Chief Executive Officer
Louis J. Arcudi III
Chief Financial Officer
Michael Culler, Ph.D.
Chief Scientific Officer
Patrick Loustau, M.S., M.A.
Chief Business Officer
Soraya Allas, M.D., PH.D.
VP, Clinical Development and Regulatory Affairs
Thomas Delale, Ph.D.
VP, Portfolio Management
David Duracher, Ph.D.
VP, Chemistry Manufacturing and Control
Bénédicte Gagnere, M.S.
Head of Finance
Board OF DIRECTORS
Chairman of the Board of Directors
Chair of the Audit and Compensation Committees
Felice Verduyn-van Weegen
Partner, Novo Ventures
Managing Partner, Kurma Partners
Partner, Andrea Partners
Stefan Larson, Ph.D.
Partner, Sectoral Asset Management
CEO, Amolyt Pharma
Scientific and Medical Advisors
David Clemmons, M.D.
University of North Carolina
Aart Jan (AJ) van der Lely, M.D., Ph.D.
Erasmus University Medical Center
AZP-3601: Clinical Advisory Board
John Bilezikian, M.D.
College of Physicians & Surgeons, Columbia University
Maria Luisa Brandi, M.D.
University of Florence
Bart L. Clarke, M.D
Aliya Khan, M.D.
Michael Mannstadt, M.D.
Massachusetts General Hospital and Harvard Medical School
Lars Rejnmark, M.D.